Stay updated with breaking news from 64026810. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report published on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. reiterated an underweight rating on shares of Nektar Therapeutics in a […]
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) will be posting its quarterly earnings results after the market closes on Tuesday, November 7th. Analysts expect Nektar Therapeutics to post earnings of ($0.18) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link. Nektar […]
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been given a consensus rating of “Reduce” by the five analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 12 month price target among […]
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has received a consensus rating of “Reduce” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average twelve-month target price among brokers that […]
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) CEO Howard W. Robin sold 19,998 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $0.78, for a total transaction of $15,598.44. Following the completion of the transaction, the chief executive officer now directly owns 919,799 […]